Header Logo

NIZAR M TANNIR

TitleProfessor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Berg SA, La Rosa S, Zhang T, Pierorazio PM, Albiges L, Beckermann KE, Campbell MT, Carlo MI, Coleman K, George DJ, Geynisman DM, Johnson R, Jonasch E, Maranchie JK, McGregor BA, Shapiro DD, Singer EA, Shuch BM, Stadler WM, Tannir NM, Zakharia Y, Vaishampayan UN, Thall PF, Msaouel P. Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting. Urol Oncol. 2024 Nov 04. PMID: 39500687.
      Citations:    
    2. Wang E, Rupe ES, Mukhida SS, Johns AC, Campbell MT, Shah AY, Zurita AJ, Gao J, Goswami S, Jonasch E, Msaouel P, Tannir NM, Hahn AW. Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2024 Sep 21. PMID: 39307587.
      Citations:    Fields:    
    3. Campbell MT, Shah AY, Msaouel P, Tannir NM, Siefker-Radtke AO, Kamat AM, Navai N, Dinney CPN, Rao P, Guo CC, Sheth RA, Venkatesan AM, Tidwell RS, Yadav SS, Gu A, Chen H, Macaluso M, Duan F, Basu S, Jindal S, Sharma P, Campbell MT, Shah AY, Msaouel P, Tannir NM, Siefker-Radtke AO, Kamat AM, Navai N, Dinney CPN, Rao P, Guo CC, Sheth RA, Venkatesan AM, Tidwell RS, Yadav SS, Gu A, Chen H, Macaluso M, Duan F, Basu S, Jindal S, Sharma P. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun. 2024 Sep 01; 4(9):2444-2453. PMID: 39207194; PMCID: PMC11406637.
      Citations:    Fields:    Translation:Humans
    4. Shanker MD, Yu ZH, Yang J, Matin S, Campbell MT, Msaouel P, Tannir N, Prajapati S, Ding Y, Lee B, Sobremonte A, Tang C. MR-Linac-guided stereotactic radiotherapy for CT-indiscernible intravascular renal cell carcinoma tumours. BJUI Compass. 2024 Oct; 5(10):913-915. PMID: 39416759; PMCID: PMC11479802.
      Citations:    
    5. Pant S, Cho BC, Kyriakopoulos CE, Spira A, Tannir N, Werner TL, Yan X, Neuteboom S, Chao R, Goel S. Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer. Invest New Drugs. 2024 Aug 21. PMID: 39168901.
      Citations:    Fields:    
    6. Tannir NM, Albig?s L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barth?l?my P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Gr?nwald V, Rini BI, Jiang R, Desilva H, Federov V, Lee CW, Motzer RJ, Tannir NM, Albig?s L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barth?l?my P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Gr?nwald V, Rini BI, Jiang R, Desilva H, Fedorov V, Lee CW, Motzer RJ. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol. 2024 Nov; 35(11):1026-1038. PMID: 39098455.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    7. Mantia CM, Jegede OA, Plimack ER, Powles T, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Choueiri TK, Rini BI, Hammers HJ, Escudier B, Albig?s L, Rosenblatt L, Atkins MB, Regan MM, McDermott DF. Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. J Immunother Cancer. 2024 Jul 25; 12(7). PMID: 39060019; PMCID: PMC11284827.
      Citations:    Fields:    Translation:Humans
    8. Lebenthal JM, Kontoyiannis PD, Hahn AW, Lim ZD, Rao P, Cheng JP, Chan B, Daw NC, Sheth RA, Karam JA, Tang C, Tannir NM, Msaouel P. Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients. Eur Urol Oncol. 2024 Jul 15. PMID: 39013742.
      Citations:    Fields:    
    9. Johns AC, Campbell MT, Gao M, Hahn AW, Lim Z, Wang E, Gao J, Shah AY, Msaouel P, Tannir NM. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. Oncologist. 2024 Jul 05; 29(7):589-595. PMID: 38478923; PMCID: PMC11224966.
      Citations: 1     Fields:    Translation:Humans
    10. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2024 Jul 04; 15(1):5621. PMID: 38965214; PMCID: PMC11224259.
      Citations:    Fields:    
    11. Pal SK, Tran B, Haanen JBAG, Hurwitz ME, Sacher A, Tannir NM, Budde LE, Harrison SJ, Klobuch S, Patel SS, Meza L, Dequeant ML, Ma A, He QA, Williams LM, Keegan A, Gurary EB, Dar H, Karnik S, Guo C, Heath H, Yuen RR, Morrow PK, Agarwal N, Srour SA, Haanen JBAG, Agarwal N. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discov. 2024 Jul 01; 14(7):1176-1189. PMID: 38583184; PMCID: PMC11215406.
      Citations: 4     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    12. Kitchlu A, Costa E Silva VT, Anand S, Kala J, Abudayyeh A, Inker LA, Rosner MH, Karam S, Gudsoorkar P, Gupta S, Chen S, Klomjit N, Leung N, Milanez T, Motwani SS, Khalid SB, Srinivasan V, Wanchoo R, Beumer JH, Liu G, Tannir NM, Orchanian-Cheff A, Geng Y, Herrmann SM, Kitchlu A, Silva VTCE, Anand S, Kala J, Abudayyeh A, Inker LA, Rosner MH, Karam S, Gudsoorkar P, Gupta S, Chen S, Klomjit N, Leung N, Milanez T, Motwani SS, Khalid SB, Srinivasan V, Wanchoo R, Beumer JH, Liu G, Tannir NM, Geng Y, Herrmann SM. Assessment of GFR in Patients with Cancer: A Statement from the American Society of Onco-Nephrology. Clin J Am Soc Nephrol. 2024 Aug 01; 19(8):1061-1072. PMID: 38848131; PMCID: PMC11321742.
      Citations: 1     Fields:    Translation:Humans
    13. Kitchlu A, Silva VTCE, Anand S, Kala J, Abudayyeh A, Inker LA, Rosner MH, Karam S, Gudsoorkar P, Gupta S, Chen S, Klomjit N, Leung N, Milanez T, Motwani SS, Khalid SB, Srinivasan V, Wanchoo R, Beumer JH, Liu G, Tannir NM, Orchanian-Cheff A, Geng Y, Herrmann SM. Assessment of GFR in Patients with Cancer Part 2: Anticancer Therapies-Perspectives from the American Society of Onco-Nephrology (ASON). Clin J Am Soc Nephrol. 2024 Aug 01; 19(8):1073-1077. PMID: 39316409; PMCID: PMC11321741.
      Citations:    Fields:    Translation:Humans
    14. Tannir NM, Formiga MN, Penkov K, Kislov N, Vasiliev A, Gunnar Skare N, Hong W, Dai S, Tang L, Qureshi A, Zalevsky J, Tagliaferri MA, George D, Agarwal N, Pal S. Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09). J Clin Oncol. 2024 Aug 10; 42(23):2800-2811. PMID: 38838287.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    15. Brugarolas J, Obara G, Beckermann KE, Rini B, Lam ET, Hamilton J, Schluep T, Yi M, Wong S, Mao ZL, Gamelin E, Tannir NM. A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2a in Patients with Advanced Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2024 Jun 03; 30(11):2402-2411. PMID: 38652038; PMCID: PMC11145158.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    16. Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist. 2024 May 03; 29(5):392-399. PMID: 38035767; PMCID: PMC11067817.
      Citations: 1     Fields:    
    17. Carril-Ajuria L, Lavaud P, Dalban C, Negrier S, Gravis G, Motzer RJ, Chevreau C, Tannir NM, Oudard S, McDermott DF, Laguerre B, Hammers HJ, Barthelemy P, Plimack ER, Borchiellini D, Gross-Goupil M, Jiang R, Lee CW, de Silva H, Rini BI, Escudier B, Albig?s L. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma. Eur J Cancer. 2024 Jun; 204:114048. PMID: 38653033.
      Citations: 2     Fields:    Translation:Humans
    18. Motzer RJ, Choueiri TK, Hutson T, Young Rha S, Puente J, Lalani AA, Winquist E, Eto M, Basappa NS, Tannir NM, Vaishampayan U, Bjarnason GA, Oudard S, Gr?nwald V, Burgents J, Xie R, McKenzie J, Powles T. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study. Eur Urol. 2024 Jul; 86(1):4-9. PMID: 38582713.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    19. Tang C, Hara K, Sherry AD, Serrano AG, Kostousov LV, Hernandez SD, Lu W, Shen L, Shah AY, Jonasch E, Karam JA, Matin SF, Tannir N, Wang J, Msaouel P, Sircar K, Solis L. YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5). PMID: 38579843.
      Citations:    Fields:    Translation:Humans
    20. Mbilinyi RH, Msaouel P, Rao P, Karam JA, Tannir NM, Tang C. Radiation Therapy for the Management of Renal Medullary Carcinoma: A Multi-Case Study. Clin Genitourin Cancer. 2024 Jun; 22(3):102065. PMID: 38556389.
      Citations:    Fields:    Translation:Humans
    21. Albiges L, McGregor BA, Heng DYC, Procopio G, de Velasco G, Taguieva-Pioger N, Mart?n-Couce L, Tannir NM, Powles T. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review. Cancer Treat Rev. 2024 Jan; 122:102652. PMID: 37980876.
      Citations:    Fields:    Translation:Humans
    22. Lu X, Tawanaie Pour Sedehi N, Su X, Yan F, Alhalabi O, Tannir NM, Malouf GG. Racial Disparities in MiT Family Translocation Renal Cell Carcinoma. Oncologist. 2023 Nov 02; 28(11):1009-1013. PMID: 37315151; PMCID: PMC10628562.
      Citations: 2     Fields:    Translation:Humans
    23. Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620. PMID: 37833193.
      Citations:    Fields:    Translation:Humans
    24. Esterberg E, Iyer S, Nagar SP, Davis KL, Tannir NM. Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2024 04; 22(2):115-125.e3. PMID: 37914609.
      Citations:    Fields:    Translation:Humans
    25. Liu XD, Zhang YT, McGrail DJ, Zhang X, Lam T, Hoang A, Hasanov E, Manyam G, Peterson CB, Zhu H, Kumar SV, Akbani R, Pilie PG, Tannir NM, Peng G, Jonasch E. SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma. Clin Cancer Res. 2023 10 02; 29(19):4002-4015. PMID: 37527013; PMCID: PMC10592192.
      Citations: 2     Fields:    Translation:HumansCells
    26. Nardo M, Yilmaz B, Nelson BE, Torres HA, Wang LS, Granwehr BP, Song J, Dalla Pria HRF, Trinh VA, Glitza Oliva IC, Patel SP, Tannir NM, Kaseb AO, Altan M, Lee SS, Miller E, Zhang H, Stephen BA, Naing A. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist. 2023 08 03; 28(8):714-721. PMID: 36952233; PMCID: PMC10400154.
      Citations: 1     Fields:    Translation:Humans
    27. Nze C, Msaouel P, Derbala MH, Stephen B, Abonofal A, Meric-Bernstam F, Tannir NM, Naing A. A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers (Basel). 2023 Jul 27; 15(15). PMID: 37568622; PMCID: PMC10417298.
      Citations: 1     
    28. Perelli L, Carbone F, Zhang L, Huang JK, Le C, Khan H, Citron F, Del Poggetto E, Gutschner T, Tomihara H, Soeung M, Minelli R, Srinivasan S, Peoples M, Lam TNA, Lundgren S, Xia R, Zhu C, Mohamed AMT, Zhang J, Sircar K, Sgambato A, Gao J, Jonasch E, Draetta GF, Futreal A, Bakouny Z, Van Allen EM, Choueiri T, Signoretti S, Msaouel P, Litchfield K, Turajlic S, Wang L, Chen YB, Di Natale RG, Hakimi AA, Giuliani V, Heffernan TP, Viale A, Bristow CA, Tannir NM, Carugo A, Genovese G. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. Nat Cancer. 2023 07; 4(7):984-1000. PMID: 37365326; PMCID: PMC10368532.
      Citations: 1     Fields:    Translation:Humans
    29. Vokshi BH, Davidson G, Tawanaie Pour Sedehi N, Helleux A, Rippinger M, Haller AR, Gantzer J, Thouvenin J, Baltzinger P, Bouarich R, Manriquez V, Zaidi S, Rao P, Msaouel P, Su X, Lang H, Tricard T, Lindner V, Surdez D, Kurtz JE, Bourdeaut F, Tannir NM, Davidson I, Malouf GG. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance. Nat Commun. 2023 05 26; 14(1):3034. PMID: 37236926; PMCID: PMC10220073.
      Citations: 5     Fields:    Translation:Humans
    30. Msaouel P, Genovese G, Tannir NM. Renal Cell Carcinoma of Variant Histology: Biology and Therapies. Hematol Oncol Clin North Am. 2023 10; 37(5):977-992. PMID: 37244822.
      Citations: 3     Fields:    Translation:Humans
    31. Soeung M, Perelli L, Chen Z, Dondossola E, Ho IL, Carbone F, Zhang L, Khan H, Le CN, Zhu C, Peoples MD, Feng N, Jiang S, Zacharias NM, Minelli R, Shapiro DD, Deem AK, Gao S, Cheng EH, Lucchetti D, Walker CL, Carugo A, Giuliani V, Heffernan TP, Viale A, Tannir NM, Draetta GF, Msaouel P, Genovese G. SMARCB1 regulates the hypoxic stress response in sickle cell trait. Proc Natl Acad Sci U S A. 2023 05 23; 120(21):e2209639120. PMID: 37186844; PMCID: PMC10214195.
      Citations: 3     Fields:    Translation:HumansAnimals
    32. Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun. 2023 05 10; 14(1):2684. PMID: 37164948; PMCID: PMC10172300.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    33. Alhalabi O, Thouvenin J, N?grier S, Vano YA, Campedel L, Hasanov E, Bakouny Z, Hahn AW, Bilen MA, Msaouel P, Choueiri TK, Viswanathan SR, Sircar K, Albiges L, Malouf GG, Tannir NM. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. Oncologist. 2023 05 08; 28(5):433-439. PMID: 36640141; PMCID: PMC10166175.
      Citations: 1     Fields:    Translation:Humans
    34. Shapiro DD, Zacharias NM, Tripathi DN, Karki M, Bertocchio JP, Soeung M, He R, Westerman ME, Gao J, Rao P, Lam TNA, Jonasch E, Perelli L, Cheng EH, Carugo A, Heffernan TP, Walker CL, Genovese G, Tannir NM, Karam JA, Msaouel P. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Clin Transl Med. 2023 05; 13(5):e1267. PMID: 37226898; PMCID: PMC10210052.
      Citations: 3     Fields:    Translation:Humans
    35. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol. 2023 Apr 18; 7(1):37. PMID: 37072571; PMCID: PMC10113233.
      Citations:    
    36. Ng CS, Chandler AG, Chen Y, Wei W, Tannir NM, Hobbs BP. Effect of scan duration on CT perfusion values in metastases from renal cell carcinoma. Res Diagn Interv Imaging. 2023 Jun; 6:100028. PMID: 39077545; PMCID: PMC11265368.
      Citations:    
    37. Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus. 2023 09; 9(5):734-741. PMID: 36863962; PMCID: PMC10460829.
      Citations: 1     Fields:    
    38. Feils AS, Erbe AK, Birstler J, Kim K, Hoch U, Currie SL, Nguyen T, Yu D, Siefker-Radtke AO, Tannir N, Tolaney SM, Diab A, Sondel PM. Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial. Cancer Immunol Immunother. 2023 Jul; 72(7):2099-2111. PMID: 36823323; PMCID: PMC10264535.
      Citations:    Fields:    Translation:Humans
    39. McQuade JL, Hammers H, Furberg H, Engert A, Andr? T, Blumenschein G, Tannir N, Baron A, Larkin J, El-Khoueiry A, Carbone DP, Thomas JM, Hennicken D, Coffey M, Motzer RJ. Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. JAMA Oncol. 2023 01 01; 9(1):102-111. PMID: 36480191; PMCID: PMC9857666.
      Citations: 3     Fields:    Translation:Humans
    40. Thouvenin J, Alhalabi O, Carlo M, Carril-Ajuria L, Hirsch L, Martinez-Chanza N, N?grier S, Campedel L, Martini D, Borchiellini D, Chahoud J, Lodi M, Barth?l?my P, Hasanov E, Hahn AW, Gil T, Viswanathan SR, Bakouny Z, Msaouel P, Asim Bilen M, Choueiri TK, Albiges L, Tannir NM, Malouf GG. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas. Oncologist. 2022 12 09; 27(12):1041-1047. PMID: 35979929; PMCID: PMC10249266.
      Citations:    
    41. Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, Jiang R, Tannir NM. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. J Immunother Cancer. 2022 12; 10(12). PMID: 36549781; PMCID: PMC9791431.
      Citations: 6     Fields:    Translation:Humans
    42. Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, Lee RJ, Jain RK, Davis N, Appleman LJ, Goodman O, Stadler WM, Gandhi S, Geynisman DM, Iacovelli R, Mellado B, Sep?lveda S?nchez JM, Figlin R, Powles T, Akella L, Orford K, Escudier B. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 10 01; 8(10):1411-1418. PMID: 36048457; PMCID: PMC9437824.
      Citations:    
    43. Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun. 2022; 33:100640. PMID: 36174377.
      Citations: 2     Fields:    
    44. Lee CH, Motzer R, Emamekhoo H, Matrana M, Percent I, Hsieh JJ, Hussain A, Vaishampayan U, Liu S, McCune S, Patel V, Shaheen M, Bendell J, Fan AC, Gartrell BA, Goodman OB, Nikolinakos PG, Kalebasty AR, Zakharia Y, Zhang Z, Parmar H, Akella L, Orford K, Tannir NM. Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. Clin Cancer Res. 2022 08 02; 28(15):3248-3255. PMID: 35576438; PMCID: PMC10202043.
      Citations:    Fields:    
    45. Hasanov E, Yeboa DN, Tucker MD, Swanson TA, Beckham TH, Rini B, Ene CI, Hasanov M, Derks S, Smits M, Dudani S, Heng DYC, Brastianos PK, Bex A, Hanalioglu S, Weinberg JS, Hirsch L, Carlo MI, Aizer A, Brown PD, Bilen MA, Chang EL, Jaboin J, Brugarolas J, Choueiri TK, Atkins MB, McGregor BA, Halasz LM, Patel TR, Soltys SG, McDermott DF, Elder JB, Baskaya MK, Yu JB, Timmerman R, Kim MM, Mut M, Markert J, Beal K, Tannir NM, Samandouras G, Lang FF, Giles R, Jonasch E. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA Cancer J Clin. 2022 09; 72(5):454-489. PMID: 35708940.
      Citations:    Fields:    
    46. Siefker-Radtke AO, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Hurwitz ME, Tannir NM. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. Eur Urol. 2022 10; 82(4):365-373. PMID: 35643589.
      Citations:    Fields:    
    47. Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420. PMID: 35442707.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    48. Meric-Bernstam F, Tannir NM, Iliopoulos O, Lee RJ, Telli ML, Fan AC, DeMichele A, Haas NB, Patel MR, Harding JJ, Voss MH, Owonikoko TK, Carthon B, Srinivasan R, Bendell JC, Jenkins Y, Whiting SH, Orford K, Bennett MK, Bauer TM. Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. Clin Cancer Res. 2022 04 14; 28(8):1540-1548. PMID: 35140121; PMCID: PMC9164172.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    49. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 04 12; 13(1):1970. PMID: 35413951; PMCID: PMC9005525.
      Citations: 1     Fields:    Translation:HumansCells
    50. Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, Plimack ER, Porta C, George S, Powles T, Donskov F, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Rini BI, McHenry MB, Lee CW, McCarthy J, Ejzykowicz F, Tannir NM, Barth?l?my P, Gr?nwald V. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022 06 01; 128(11):2085-2097. PMID: 35383908; PMCID: PMC9543316.
      Citations:    Fields:    Translation:Humans
    51. Tannir NM, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Siefker-Radtke AO, Hurwitz ME. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. J Immunother Cancer. 2022 04; 10(4). PMID: 35444058; PMCID: PMC9021810.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    52. Choueiri TK, Atkins MB, Bakouny Z, Bratslavsky G, Braun DA, Haas NB, Haanen JBAG, Hakimi AA, Jewett MAS, Jonasch E, Kaelin WG, Kapur P, Labaki C, Lewis B, McDermott DF, Pal SK, Pels K, Poteat S, Powles T, Rathmell WK, Rini BI, Signoretti S, Tannir NM, Uzzo RG, Hammers HJ, Albiges L. From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clin Cancer Res. 2022 03 01; 28(5):831-839. PMID: 34965942; PMCID: PMC9223120.
      Citations:    Fields:    Translation:Humans
    53. Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel P. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel). 2021 Nov 30; 13(23). PMID: 34885132; PMCID: PMC8656882.
      Citations: 2     
    54. Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Plimack ER, Choueiri TK, Rini BI, Hammers HJ, Escudier B, Albiges L, Huo S, Del Tejo V, Stwalley B, Atkins MB, McDermott DF. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clin Cancer Res. 2021 12 15; 27(24):6687-6695. PMID: 34759043; PMCID: PMC9357269.
      Citations: 3     Fields:    Translation:Humans
    55. Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Leung D, Saggi SS, Lee CW, McHenry MB, Motzer RJ, Barth?l?my P. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. Eur Urol. 2022 03; 81(3):266-271. PMID: 34750035; PMCID: PMC10202028.
      Citations:    Fields:    Translation:Humans
    56. Schmidinger M, Motzer RJ, Rink M, Retz M, McCaffrey JA, De Giorgi U, Caserta C, Duran I, Benzaghou F, Clary DO, Choueiri TK, Tannir NM, Rolland F, Staehler M, Csoszi T, Albiges L. Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. Acta Oncol. 2022 Jan; 61(1):52-57. PMID: 34736367; PMCID: PMC9357268.
      Citations:    Fields:    Translation:Humans
    57. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375. PMID: 34737281; PMCID: PMC8569213.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    58. Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, Wang J, Jonasch E, Choi S, Nguyen QN, Das P, Prajapati S, Yu Z, Khan K, Powell S, Murthy R, Sircar K, Tannir NM. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021 12; 22(12):1732-1739. PMID: 34717797.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    59. Pieretti AC, Shapiro DD, Westerman ME, Hwang H, Wang X, Segarra LA, Campbell MT, Tannir NM, Jonasch E, Matin SF, Wood CG, Karam JA. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol. 2021 12; 39(12):837.e9-837.e17. PMID: 34551888; PMCID: PMC9486901.
      Citations: 1     Fields:    Translation:Humans
    60. Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer. 2021 12; 19(6):e401-e408. PMID: 34625389.
      Citations: 1     Fields:    Translation:Humans
    61. Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R, Scheffold C, Wang E, Aftab DT, Escudier B, George DJ. Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Sep 15; 21(1):1023. PMID: 34525968; PMCID: PMC8442414.
      Citations:    Fields:    
    62. Alhalabi O, Tannir NM, Thouvenin J, Mart?nez Chanz? N, Lang H, Barth?l?my P, Malouf GG. Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions. Cancers (Basel). 2021 Aug 27; 13(17). PMID: 34503152; PMCID: PMC8431384.
      Citations: 4     
    63. Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R, Scheffold C, Wang E, Aftab DT, Escudier B, George DJ. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Aug 07; 21(1):904. PMID: 34364385; PMCID: PMC8349489.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    64. Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open. 2021 08 02; 4(8):e2122998. PMID: 34459906; PMCID: PMC8406081.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    65. De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. 2022 05; 129(5):610-620. PMID: 34228889; PMCID: PMC10097479.
      Citations: 1     Fields:    Translation:Humans
    66. Pieretti AC, Westerman ME, Childs A, Millward N, Shapiro DD, Sircar K, Rao P, Jonasch E, Campbell MT, Tannir NM, Matin SF, Wood CG, Karam JA. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol. 2021 11; 39(11):790.e17-790.e23. PMID: 34301458.
      Citations:    Fields:    Translation:Humans
    67. Harding JJ, Telli M, Munster P, Voss MH, Infante JR, DeMichele A, Dunphy M, Le MH, Molineaux C, Orford K, Parlati F, Whiting SH, Bennett MK, Tannir NM, Meric-Bernstam F. A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2021 09 15; 27(18):4994-5003. PMID: 34285061; PMCID: PMC9401498.
      Citations: 5     Fields:    Translation:Humans
    68. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer. 2022 02; 20(1):e16-e24. PMID: 34362693.
      Citations:    Fields:    Translation:Humans
    69. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer. 2021 07; 9(7). PMID: 34326169; PMCID: PMC8323401.
      Citations: 1     Fields:    Translation:Humans
    70. Vogelzang NJ, Monnette AM, Wang Y, Wan Y, Xie Y, Robert NJ, Tannir NM. Real-world Clinical Effectiveness of Lenvatinib/Everolimus in a Heavily Pretreated Advanced/Metastatic Renal Cell Carcinoma Population in the US Community Oncology Setting. Clin Genitourin Cancer. 2021 12; 19(6):531-539. PMID: 34112611.
      Citations:    Fields:    Translation:Humans
    71. Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther. 2021; 14:3037-3049. PMID: 33994796; PMCID: PMC8114359.
      Citations: 2     Translation:CTClinical Trials
    72. Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel). 2021 Apr 30; 13(9). PMID: 33946504; PMCID: PMC8124338.
      Citations: 2     
    73. Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, Jonasch E, Shah AY, Campbell MT, Msaouel P, Tannir NM. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. Oncologist. 2021 06; 26(6):476-482. PMID: 33792094; PMCID: PMC8176993.
      Citations: 4     Fields:    Translation:Humans
    74. Tannir NM, Papadopoulos KP, Wong DJ, Aljumaily R, Hung A, Afable M, Kim JS, Ferry D, Drakaki A, Bendell J, Naing A. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408. PMID: 33709428; PMCID: PMC8251721.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    75. Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer. 2021 07 15; 149(2):387-393. PMID: 33739450.
      Citations: 2     Fields:    Translation:Humans
    76. Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Med. 2021 04; 10(7):2341-2349. PMID: 33650321; PMCID: PMC7982609.
      Citations: 2     Fields:    Translation:Humans
    77. Choueiri TK, Atkins MB, Bakouny Z, Carlo MI, Drake CG, Jonasch E, Kapur P, Lewis B, Linehan WM, Mitchell MJ, Pal SK, Pels K, Poteat S, Rathmell WK, Rini BI, Signoretti S, Tannir N, Uzzo R, Wood CG, Hammers HJ. Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. J Natl Cancer Inst. 2021 03 01; 113(3):234-243. PMID: 32359162; PMCID: PMC7936057.
      Citations: 6     Fields:    Translation:HumansAnimals
    78. Esagian SM, Ziogas IA, Kosmidis D, Hossain MD, Tannir NM, Msaouel P. Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis. Cancers (Basel). 2021 Feb 09; 13(4). PMID: 33572149; PMCID: PMC7915816.
      Citations:    
    79. Msaouel P, Genovese G, Gao J, Sen S, Tannir NM. TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment? Expert Opin Ther Targets. 2021 02; 25(2):141-151. PMID: 33356674.
      Citations: 2     Fields:    Translation:HumansAnimals
    80. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Mol Cancer Res. 2021 03; 19(3):395-402. PMID: 33323389.
      Citations: 1     Fields:    Translation:Humans
    81. Zoumpourlis P, Genovese G, Tannir NM, Msaouel P. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. Clin Genitourin Cancer. 2021 04; 19(2):103-116. PMID: 33358151; PMCID: PMC8169717.
      Citations: 9     Fields:    Translation:Humans
    82. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16. PMID: 33187886.
      Citations: 1     Fields:    Translation:Humans
    83. Tomihara H, Carbone F, Perelli L, Huang JK, Soeung M, Rose JL, Robinson FS, Lissanu Deribe Y, Feng N, Takeda M, Inoue A, Poggetto ED, Deem AK, Maitra A, Msaouel P, Tannir NM, Draetta GF, Viale A, Heffernan TP, Bristow CA, Carugo A, Genovese G. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. Cancer Res. 2021 01 15; 81(2):332-343. PMID: 33158812; PMCID: PMC8728103.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    84. Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Tomita Y, Castellano D, Rini BI, Choueiri TK, Saggi SS, McHenry MB, Motzer RJ, Barth?l?my P, Grimm MO. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020 11; 5(6):e001079. PMID: 33246931; PMCID: PMC7703447.
      Citations: 66     Translation:HumansCTClinical Trials
    85. Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open. 2020 11; 5(6):e001073. PMID: 33229506; PMCID: PMC7684827.
      Citations:    Translation:HumansCTClinical Trials
    86. Tarek N, Said R, Andersen CR, Suki TS, Foglesong J, Herzog CE, Tannir NM, Patel S, Ratan R, Ludwig JA, Daw NC. Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience. Cancers (Basel). 2020 Oct 11; 12(10). PMID: 33050651; PMCID: PMC7599660.
      Citations:    
    87. Hasanov E, Gao J, Tannir NM. The Immunotherapy Revolution in Kidney Cancer Treatment: Scientific Rationale and First-Generation Results. Cancer J. 2020 Sep/Oct; 26(5):419-431. PMID: 32947310.
      Citations: 6     Fields:    Translation:Humans
    88. Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, Pignon JC, Ficial M, George S, Powles T, Donskov F, Harrison MR, Tykodi SS, Kocsis J, Ravaud A, Pal SK, Murad AM, Ishii Y, Saggi SS, McHenry MB, Rini BI, Frontera OA, Barth?l?my P, Rodriguez-Cid JR. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. 2021 01 01; 27(1):78-86. PMID: 32873572; PMCID: PMC8589223.
      Citations: 37     Fields:    Translation:HumansCells
    89. Westerman ME, Shapiro DD, Tannir NM, Campbell MT, Matin SF, Karam JA, Wood CG. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int. 2020 12; 126(6):745-753. PMID: 32623821.
      Citations: 3     Fields:    Translation:Humans
    90. Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Plimack ER, Procopio G, McDermott DF, Castellano D, Choueiri TK, Donskov F, Gurney H, Richardet M, Peltola K, Alva AS, Carducci M, Wagstaff J, Chevreau C, Fukasawa S, Tomita Y, Gauler TC, Kollmannsberger CK, Larkin J, Cella D, McHenry MB, Saggi SS, Tannir NM, Oudard S, Schutz FA. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020 09 15; 126(18):4156-4167. PMID: 32673417; PMCID: PMC8415096.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    91. Motzer RJ, Escudier B, McDermott DF, Melichar B, Powles T, Donskov F, Plimack ER, Hammers HJ, George S, Porta C, Neiman V, Ravaud A, Choueiri TK, Rini BI, Kollmannsberger CK, Tykodi SS, Grimm MO, Gurney H, Leibowitz-Amit R, Geertsen PF, Amin A, Tomita Y, McHenry MB, Saggi SS, Tannir NM, Ar?n Frontera O, Barth?l?my P, Gr?nwald V, Salman P. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020 07; 8(2). PMID: 32661118; PMCID: PMC7359377.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    92. Msaouel P, Walker CL, Genovese G, Tannir NM. Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye. Mol Cell Oncol. 2020; 7(5):1777060. PMID: 32944636; PMCID: PMC7469578.
      Citations: 4     
    93. McIntosh AG, Umbreit EC, Holland LC, Gu C, Tannir NM, Matin SF, Karam JA, Culp SH, Wood CG. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer. 2020 09 01; 126(17):3950-3960. PMID: 32515845.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    94. Gupta S, Kang HC, Sun J, Matrana MR, Tannir NM, Choi H. Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC). Abdom Radiol (NY). 2020 06; 45(6):1872-1882. PMID: 31822966.
      Citations:    Fields:    Translation:Humans
    95. Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2021 02; 19(1):22-31.e5. PMID: 32675015; PMCID: PMC10014037.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    96. Diab A, Tannir NM, Bentebibel SE, Hwu P, Papadimitrakopoulou V, Haymaker C, Kluger HM, Gettinger SN, Sznol M, Tykodi SS, Curti BD, Tagliaferri MA, Zalevsky J, Hannah AL, Hoch U, Aung S, Fanton C, Rizwan A, Iacucci E, Liao Y, Bernatchez C, Hurwitz ME, Cho DC. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discov. 2020 08; 10(8):1158-1173. PMID: 32439653.
      Citations: 62     Fields:    Translation:HumansCellsCTClinical Trials
    97. Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun. 2020 05 01; 11(1):2135. PMID: 32358509; PMCID: PMC7195420.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    98. Msaouel P, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Karki M, Seervai RNH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM, Malouf GG, Pili? PG, Vokshi BH, Davidson I. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. 2020 05 11; 37(5):720-734.e13. PMID: 32359397; PMCID: PMC7288373.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    99. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1). PMID: 32188704; PMCID: PMC7078933.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    100. Figlin RA, Tannir NM, Uzzo RG, Tykodi SS, Chen DYT, Master V, Kapoor A, Vaena D, Lowrance W, Bratslavsky G, DeBenedette M, Gamble A, Plachco A, Norris MS, Horvatinovich J, Tcherepanova IY, Nicolette CA, Wood CG, ADAPT study group. Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2020 05 15; 26(10):2327-2336. PMID: 32034074.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    101. Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020 03; 127:67-75. PMID: 31986451; PMCID: PMC7350510.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    102. Dong Y, Dinatale RG, Chen YB, Su X, Mano R, Blum KA, Yao H, Karam JA, Ho TH, Tickoo SK, Russo P, Hsieh JJ, Tannir NM, Hakimi AA, Malouf GG, Flippot R, Comp?rat E, Roupr?t M, Mouawad R, Spano JP, Khayat D. Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Sci Rep. 2020 01 20; 10(1):701. PMID: 31959902; PMCID: PMC6971072.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    103. Adashek JJ, Genovese G, Tannir NM, Msaouel P. Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. Cancer Treat Res Commun. 2020 Jan 03; 23:100166. PMID: 31935623.
      Citations: 8     Fields:    
    104. Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, Donskov F, Bjarnason GA, Beuselinck B, De Velasco G, Iafolla M, Duh MS, Huynh L, Chang R, Zanotti G, Ramaswamy K, Choueiri TK, Tannir NM, Heng DYC. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. Eur Urol Oncol. 2021 02; 4(1):102-111. PMID: 31786162.
      Citations: 7     Fields:    Translation:Humans
    105. Escudier B, Motzer RJ, Tannir NM, Porta C, Tomita Y, Maurer MA, McHenry MB, Rini BI. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. Eur Urol. 2020 04; 77(4):449-453. PMID: 31732098; PMCID: PMC7521478.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    106. Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019 11; 20(11):1544-1555. PMID: 31563517; PMCID: PMC8436252.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    107. Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist. 2020 03; 25(3):252-258. PMID: 32162795; PMCID: PMC7066696.
      Citations: 23     Fields:    Translation:Humans
    108. Alhalabi O, Karam JA, Tannir NM. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology. Curr Opin Urol. 2019 09; 29(5):521-525. PMID: 31305271.
      Citations: 1     Fields:    Translation:Humans
    109. Motzer RJ, Rini BI, McDermott DF, Hammers HJ, Carducci MA, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, McHenry MB, Mekan S, Tannir NM, CheckMate 214 investigators, Ar?n Frontera O, Salman P, Barth?l?my P, Oudard S, Gr?nwald V. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 10; 20(10):1370-1385. PMID: 31427204; PMCID: PMC7497870.
      Citations: 203     Fields:    Translation:HumansCTClinical Trials
    110. Hasanov E, Tidwell RSS, Fernandez P, Park L, McMichael C, Tannir NM, Jonasch E. Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma. Clin Genitourin Cancer. 2019 12; 17(6):451-456. PMID: 31439537.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    111. Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol. 2020 10; 3(5):687-694. PMID: 31272939; PMCID: PMC6938577.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    112. Ning MS, Deegan BJ, Ho JC, Chapman BV, Bishop AJ, Allen PK, Tannir NM, Amini B, Briere TM, Wang XA, Tatsui CE, Rhines LD, Brown PD, Li J, Ghia AJ. Low incidence of late failure and toxicity after spine stereotactic radiosurgery: Secondary analysis of phase I/II trials with long-term follow-up. Radiother Oncol. 2019 09; 138:80-85. PMID: 31252298.
      Citations: 2     Fields:    Translation:Humans
    113. Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, Singh RR, Kim TB, Kawakami F, Routbort MJ, Alouch N, Chow CB, Tang X, Lu W, Brimo F, Matin SF, Wood CG, Tannir NM, Wistuba II, Chen K, Wang J, Medeiros LJ, Karam JA, Tamboli P, Sircar K. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 11; 32(11):1698-1707. PMID: 31231128.
      Citations: 10     Fields:    Translation:HumansCells
    114. Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer. 2019 06; 114:67-75. PMID: 31075726; PMCID: PMC7537491.
      Citations: 27     Fields:    Translation:Humans
    115. Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, Tetzlaff MT, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Aung S, Hwu P, Curti BD, Tannir NM, Sznol M, Diab A. A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R??-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. Cancer Discov. 2019 06; 9(6):711-721. PMID: 30988166.
      Citations: 74     Fields:    Translation:HumansCells
    116. Lemke EA, Shah AY, Campbell M, Tannir NM. Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis. J Adv Pract Oncol. 2019 May-Jun; 10(4):333-339. PMID: 33343982; PMCID: PMC7520741.
      Citations: 1     
    117. Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G, Malouf GG, Sgambato A. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell. 2019 02 11; 35(2):204-220.e9. PMID: 30753823; PMCID: PMC7876656.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    118. Sternberg CN, Motzer RJ, Hutson TE, Choueiri TK, Kollmannsberger C, Bjarnason GA, Porta C, Dezzani L, Han J, Tannir NM, Gr?nwald V. COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2019 12; 17(6):425-435.e4. PMID: 31601514; PMCID: PMC7518515.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    119. Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019 01 06; 7(1):2. PMID: 30612580; PMCID: PMC6322290.
      Citations: 82     Fields:    Translation:Humans
    120. Carlo MI, Borchiellini D, Voss MH, George S, Chevreau C, Chism DD, Amin A, Bilen MA, Bosse D, Su X, Choueiri TK, Tannir NM, Boil?ve A, Barth?l?my P, Oudard S, Landman-Parker J, Tabone MD, Coulomb-L'hermine A, Malouf GG. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders. J Immunother Cancer. 2018 12 27; 6(1):159. PMID: 30591082; PMCID: PMC6307255.
      Citations: 14     Fields:    Translation:Humans
    121. Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell. 2018 11 12; 34(5):775-791.e3. PMID: 30423297; PMCID: PMC8098754.
      Citations: 67     Fields:    Translation:HumansAnimalsCells
    122. Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Eur J Cancer. 2018 11; 104:188-194. PMID: 30380460.
      Citations: 20     Fields:    Translation:Humans
    123. Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer. 2019 02; 17(1):1-6. PMID: 30287223; PMCID: PMC6348017.
      Citations: 13     Fields:    Translation:Humans
    124. Zhang J, Ye Y, Chang DW, Lin SH, Huang M, Tannir NM, Matin S, Karam JA, Wood CG, Chen ZN, Wu X. Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. Am J Pathol. 2018 11; 188(11):2487-2496. PMID: 30201497; PMCID: PMC6207099.
      Citations: 16     Fields:    Translation:Humans
    125. Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018 Nov; 70:127-137. PMID: 30173085.
      Citations: 93     Fields:    Translation:Humans
    126. Shu X, Gu J, Huang M, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X, Ye Y. Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis. 2018 05 28; 39(6):752-757. PMID: 29635281; PMCID: PMC5972595.
      Citations: 8     Fields:    Translation:Humans
    127. Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2018 06 01; 36(16):1588-1593. PMID: 29641297; PMCID: PMC6804828.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    128. CheckMate 214 Investigators, Motzer RJ, Tannir NM, McDermott DF, Ar?n Frontera O, Melichar B, Choueiri TK, Plimack ER, Barth?l?my P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 05; 378(14):1277-1290. PMID: 29562145; PMCID: PMC5972549.
      Citations: 1163     Fields:    Translation:HumansCTClinical Trials
    129. Tannir NM, Pal SK, Atkins MB. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. Oncologist. 2018 05; 23(5):540-555. PMID: 29487224; PMCID: PMC5947457.
      Citations: 29     Fields:    Translation:Humans
    130. Msaouel P, Tannir NM, Walker CL. A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma. Clin Cancer Res. 2018 05 01; 24(9):2044-2049. PMID: 29440190.
      Citations: 20     Fields:    Translation:HumansAnimals
    131. Tannir N, Hammers H, Amin A. First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy. Curr Med Res Opin. 2018 05; 34(5):825-831. PMID: 29297707.
      Citations: 8     Fields:    Translation:Humans
    132. Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, Choueiri TK. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. J Clin Oncol. 2018 03 10; 36(8):757-764. PMID: 29377755; PMCID: PMC6804841.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    133. Pan T, Lin SC, Yu KJ, Yu G, Song JH, Lewis VO, Bird JE, Moon B, Lin PP, Tannir NM, Jonasch E, Wood CG, Gallick GE, Yu-Lee LY, Lin SH, Satcher RL. BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia. 2018 01; 20(1):32-43. PMID: 29190493; PMCID: PMC5711998.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    134. Gardner CS, Ensor JE, Ahrar K, Huang SY, Sabir SH, Tannir NM, Lewis VO, Tam AL. Cryoablation of Bone Metastases from Renal Cell Carcinoma for Local Tumor Control. J Bone Joint Surg Am. 2017 Nov 15; 99(22):1916-1926. PMID: 29135665.
      Citations: 11     Fields:    Translation:Humans
    135. Msaouel P, Malouf GG, Tannir NM. Metabolic Derangements in Succinate Dehydrogenase B-Mutated Renal-Cell Carcinomas: More Than Meets the Eye? JCO Precis Oncol. 2017 Nov; 1:1-4. PMID: 35172487.
      Citations:    Fields:    
    136. Zhu J, Tu H, Matin SF, Tannir NM, Wood CG, Wu X. Glycemic index, glycemic load and carbohydrate intake in association with risk of renal cell carcinoma. Carcinogenesis. 2017 10 26; 38(11):1129-1135. PMID: 28968893; PMCID: PMC5862287.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    137. Kang HC, Gupta S, Wei W, Lu L, Matrana MR, Tannir NM, Choi H. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy. AJR Am J Roentgenol. 2017 Dec; 209(6):1278-1284. PMID: 29064751; PMCID: PMC5722466.
      Citations: 2     Fields:    Translation:Humans
    138. Shah AY, Tannir NM. Editorial Comment. Urology. 2017 11; 109:132. PMID: 28867144.
      Citations:    Fields:    
    139. Yennurajalingam S, Tannir NM, Williams JL, Lu Z, Hess KR, Frisbee-Hume S, House HL, Lim ZD, Lim KH, Lopez G, Reddy A, Azhar A, Wong A, Patel SM, Kuban DA, Kaseb AO, Cohen L, Bruera E. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer. J Natl Compr Canc Netw. 2017 09; 15(9):1111-1120. PMID: 28874596.
      Citations: 19     Fields:    Translation:HumansAnimals
    140. Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017 Dec 15; 123(24):4823-4831. PMID: 28832979; PMCID: PMC5731248.
      Citations: 36     Fields:    Translation:HumansCells
    141. Tannir NM, Su X, Flippot R, Mouawad R, Spano JP, Roupr?t M, Comp?rat E, Bitker MO, Parra J, Vaessen C, Allanic F, Manach Q, Khayat D, Malouf GG. Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma. Sci Rep. 2017 08 17; 7(1):8540. PMID: 28819235; PMCID: PMC5561098.
      Citations: 6     Fields:    Translation:Humans
    142. Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, Rathmell WK, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. Cancer Res. 2017 10 01; 77(19):5313-5326. PMID: 28807937; PMCID: PMC5626626.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    143. Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer. 2017 Aug 10. PMID: 28870517; PMCID: PMC5809227.
      Citations: 7     Fields:    
    144. Su X, Zhang J, Thompson EJ, Gowrishankar B, Houldsworth J, Weinstein JN, Tost J, Broom BM, Tannir NM, Mouawad R, Comp?rat E, Roupr?t M, Allanic F, Parra J, Bitker MO, Khayat D, Spano JP, Malouf GG. NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas. Cancer Res. 2017 09 15; 77(18):4835-4845. PMID: 28754676; PMCID: PMC6211291.
      Citations: 17     Fields:    Translation:HumansCells
    145. Giles RH, Choueiri TK, Heng DY, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A, Albiges L. Recommendations for the Management of Rare Kidney Cancers. Eur Urol. 2017 12; 72(6):974-983. PMID: 28720391.
      Citations: 19     Fields:    Translation:HumansCells
    146. Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, Kawakami F, Trevisan P, Jonasch E, Chow CW, Canales JR, Tamboli P, Tannir N, Wood C, Monzon F, Baggerly K, Varella-Garcia M, Czerniak B, Wistuba I, Mills G, Shaw K, Chen K, Sircar K. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clin Cancer Res. 2017 Nov 01; 23(21):6686-6696. PMID: 28710314; PMCID: PMC5683086.
      Citations: 26     Fields:    Translation:Humans
    147. Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK. Renal Medullary Carcinoma: Establishing Standards in Practice. J Oncol Pract. 2017 07; 13(7):414-421. PMID: 28697319; PMCID: PMC5508447.
      Citations: 18     Fields:    Translation:Humans
    148. Msaouel P, Zurita AJ, Huang S, Jonasch E, Tannir NM. Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. Oncotarget. 2017 Jun 27; 8(26):42149-42158. PMID: 28178674; PMCID: PMC5522056.
      Citations: 2     Fields:    Translation:Humans
    149. Tannir NM, Figlin RA, Gore ME, Michaelson MD, Motzer RJ, Porta C, Rini BI, Hoang C, Lin X, Escudier B. Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. Clin Genitourin Cancer. 2017 Jun 20. PMID: 28711490; PMCID: PMC6736765.
      Citations: 8     Fields:    
    150. Tannir NM, Flippot R, Comp?rat E, Malouf GG. Papillary Renal Cell Carcinoma: A Family Portrait. Eur Urol. 2018 01; 73(1):79-80. PMID: 28642022.
      Citations: 2     Fields:    Translation:Humans
    151. Shu X, Purdue MP, Ye Y, Tu H, Wood CG, Tannir NM, Wang Z, Albanes D, Gapstur SM, Stevens VL, Rothman N, Chanock SJ, Wu X. Potential Susceptibility Loci Identified for Renal Cell Carcinoma by Targeting Obesity-Related Genes. Cancer Epidemiol Biomarkers Prev. 2017 09; 26(9):1436-1442. PMID: 28626070; PMCID: PMC5581698.
      Citations: 1     Fields:    Translation:Humans
    152. Gu J, Herrera LA, Tannir NM, Zhang S, Matin S, Karam JA, Wood CG, Wu X, Mendoza-P?rez J. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. Cancer. 2017 Sep 15; 123(18):3617-3627. PMID: 28543182; PMCID: PMC5589484.
      Citations: 13     Fields:    Translation:HumansCells
    153. Joseph RW, Shah AY, Tannir NM, Malouf GG. Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. Clin Adv Hematol Oncol. 2017 May; 15(5):409-418. PMID: 28591094.
      Citations: 5     Fields:    Translation:Humans
    154. Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537. PMID: 28411072; PMCID: PMC5597336.
      Citations: 20     Fields:    Translation:Humans
    155. Rao P, Matrana MR, Cauley DH, Wood CG, Patel S, Tannir NM, Teegavarapu PS. Outcomes of Adults With Ewing Sarcoma Family of Tumors (ESFT) of the Kidney: A Single-Institution Experience. Am J Clin Oncol. 2017 Apr; 40(2):189-193. PMID: 25222071; PMCID: PMC4372498.
      Citations: 5     Fields:    Translation:Humans
    156. Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN, Tannir NM. A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Ann Oncol. 2017 04 01; 28(4):804-808. PMID: 28049139; PMCID: PMC5834088.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    157. Su X, Yao H, Thompson EJ, Doss DJ, Tannir NM, Classe M, Malouf GG, Gr?goire V, Lenobin J, Fantoni JC, Sudour-Bonnange H, Khayat D, Aubert S, Leroy X. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas. Histopathology. 2017 Jun; 70(7):1089-1097. PMID: 28106924.
      Citations: 20     Fields:    Translation:Humans
    158. Leal I, Milbury K, Engebretson J, Matin S, Jonasch E, Tannir N, Wood CG, Cohen L. Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma. Palliat Support Care. 2018 04; 16(2):146-154. PMID: 28262086; PMCID: PMC5587362.
      Citations: 2     Fields:    Translation:Humans
    159. de Velasco G, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK, Culhane AC, Fay AP. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist. 2017 03; 22(3):286-292. PMID: 28220024; PMCID: PMC5344647.
      Citations: 26     Fields:    Translation:Humans
    160. Tannir NM, Schwab G, Gr?nwald V. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. Curr Oncol Rep. 2017 Feb; 19(2):14. PMID: 28247252; PMCID: PMC5331092.
      Citations: 22     Fields:    Translation:Humans
    161. Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370. PMID: 28216278.
      Citations: 8     Fields:    Translation:Humans
    162. Jensen G, Tang C, Hess KR, Bishop AJ, Pan HY, Li J, Yang JN, Tannir NM, Amini B, Tatsui C, Rhines L, Brown PD, Ghia AJ. Internal validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic radiosurgery. J Radiosurg SBRT. 2017; 5(1):25-34. PMID: 29296460; PMCID: PMC5675505.
      Citations: 5     
    163. Shah AY, Karam JA, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM, Malouf GG. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792. PMID: 27860149; PMCID: PMC6857178.
      Citations: 22     Fields:    Translation:Humans
    164. Shu X, Hildebrandt MA, Gu J, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X. MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. Br J Cancer. 2017 01 03; 116(1):77-84. PMID: 27907930; PMCID: PMC5220154.
      Citations: 19     Fields:    Translation:HumansCells
    165. Msaouel P, Tannir NM, Malouf GG. Linking Gene Mutations to Clinical Outcomes and Response to Therapy in Clear-cell Renal Cell Carcinoma: Ready for Prime Time? Eur Urol. 2017 03; 71(3):415-416. PMID: 27816301.
      Citations: 1     Fields:    Translation:Humans
    166. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR. Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 10 10; 34(29):3562-3569. PMID: 27528724; PMCID: PMC5657013.
      Citations: 72     Fields:    Translation:HumansCTClinical Trials
    167. de Velasco G, Miao D, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen EM, Choueiri TK. Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. Cancer Immunol Res. 2016 10; 4(10):820-822. PMID: 27538576; PMCID: PMC5050137.
      Citations: 32     Fields:    Translation:Humans
    168. Matrana MR, Baiomy A, Campbell M, Alamri S, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Elsayes KM, Tannir NM. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. Clin Genitourin Cancer. 2017 04; 15(2):e205-e208. PMID: 27568124.
      Citations: 11     Fields:    Translation:Humans
    169. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer. 2016; 4:36. PMID: 27330809; PMCID: PMC4915058.
      Citations: 31     Fields:    
    170. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ, METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul; 17(7):917-927. PMID: 27279544.
      Citations: 291     Fields:    Translation:HumansCTClinical Trials
    171. Su X, Zhang J, Creighton CJ, Ho TH, Lu Y, Karam JA, Tamboli P, Wood CG, Jelinek J, Tannir NM, Malouf GG, Raynal NJ, Allanick F, Mouawad R, Spano JP, Khayat D. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clin Cancer Res. 2016 Dec 15; 22(24):6236-6246. PMID: 27256309; PMCID: PMC5135666.
      Citations: 22     Fields:    Translation:HumansCells
    172. Milbury K, Lopez G, Spelman A, Wood C, Matin SF, Tannir NM, Jonasch E, Pisters L, Wei Q, Cohen L. Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support. Psychooncology. 2017 09; 26(9):1361-1368. PMID: 27145447; PMCID: PMC5094904.
      Citations: 11     Fields:    Translation:Humans
    173. Thomas AZ, Adibi M, Slack RS, Borregales LD, Merrill MM, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. 2016 Sep; 196(3):678-84. PMID: 27036304; PMCID: PMC5014677.
      Citations: 12     Fields:    Translation:Humans
    174. Chittoria N, Haddad H, Elson P, Tannir NM, Wood LS, Dreicer R, Garcia JA, Rini BI, Jonasch E. Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. BMC Cancer. 2016 Mar 29; 16:254. PMID: 27026229; PMCID: PMC4810513.
      Citations:    Fields:    Translation:Humans
    175. Tao R, Bishop AJ, Brownlee Z, Allen PK, Settle SH, Chang EL, Wang X, Amini B, Tannir NM, Tatsui C, Rhines LD, Brown PD, Ghia AJ. Stereotactic Body Radiation Therapy for Spinal Metastases in the Postoperative Setting: A Secondary Analysis of Mature Phase 1-2 Trials. Int J Radiat Oncol Biol Phys. 2016 08 01; 95(5):1405-1413. PMID: 27209509.
      Citations: 14     Fields:    Translation:HumansPHPublic Health
    176. Tu SM, Bilen MA, Tannir NM. Personalised cancer care: promises and challenges of targeted therapy. J R Soc Med. 2016 Mar; 109(3):98-105. PMID: 26933155; PMCID: PMC4794967.
      Citations: 8     Fields:    Translation:Humans
    177. Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Pal SK, Su X, Sircar K, Tamboli P, Jonasch E, Tannir NM, Wood CG, Karam JA, Malouf GG, Khayat D. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol. 2016 08; 70(2):348-57. PMID: 26895810.
      Citations: 51     Fields:    Translation:Humans
    178. Ghia AJ, Chang EL, Bishop AJ, Pan HY, Boehling NS, Amini B, Allen PK, Li J, Rhines LD, Tannir NM, Tatsui CE, Brown PD, Yang JN. Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of Phase I/II trials. J Neurosurg Spine. 2016 May; 24(5):829-36. PMID: 26799117.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    179. Borregales LD, Kim DY, Staller AL, Qiao W, Thomas AZ, Adibi M, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26. PMID: 26707613; PMCID: PMC4835261.
      Citations: 4     Fields:    Translation:Humans
    180. Matrana MR, Bathala T, Campbell MT, Duran C, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience. BJU Int. 2016 08; 118(2):264-71. PMID: 26573089; PMCID: PMC4870151.
      Citations: 7     Fields:    Translation:Humans
    181. Gu J, Tannir NM, Matin SF, Karam JA, Huang M, Chang DW, Wood CG, Wu X, Mendoza-P?rez J, Herrera LA. Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study. Clin Cancer Res. 2016 Apr 15; 22(8):2074-82. PMID: 26655847; PMCID: PMC4834236.
      Citations: 12     Fields:    Translation:HumansCells
    182. Lee SH, Tatsui CE, Ghia AJ, Amini B, Li J, Zavarella SM, Tannir NM, Brown PD, Rhines LD. Can the spinal instability neoplastic score prior to spinal radiosurgery predict compression fractures following stereotactic spinal radiosurgery for metastatic spinal tumor?: a post hoc analysis of prospective phase II single-institution trials. J Neurooncol. 2016 Feb; 126(3):509-17. PMID: 26643804.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    183. Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74. PMID: 26626617; PMCID: PMC4879109.
      Citations: 100     Fields:    Translation:HumansCTClinical Trials
    184. Jiang Y, Zhang J, Zheng X, Chen Y, Thompson EJ, Weinstein JN, Yuan Y, Broaddus R, Tannir NM, Lu KH, Su X, Malouf GG, Spano JP, Khayat D. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. Oncotarget. 2015 Nov 24; 6(37):39865-76. PMID: 26431491; PMCID: PMC4741866.
      Citations: 10     Fields:    Translation:HumansCells
    185. Melkonian SC, Daniel CR, Ye Y, Tannir NM, Karam JA, Matin SF, Wood CG, Wu X. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma. Cancer. 2016 Jan 01; 122(1):108-15. PMID: 26551148; PMCID: PMC5016565.
      Citations: 13     Fields:    Translation:Humans
    186. Amini B, Beaman CB, Madewell JE, Allen PK, Rhines LD, Tatsui CE, Tannir NM, Li J, Brown PD, Ghia AJ. Osseous Pseudoprogression in Vertebral Bodies Treated with Stereotactic Radiosurgery: A Secondary Analysis of Prospective Phase I/II Clinical Trials. AJNR Am J Neuroradiol. 2016 Feb; 37(2):387-92. PMID: 26494690; PMCID: PMC4752915.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    187. Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol. 2015 Dec; 26(12):2507-8. PMID: 26487577; PMCID: PMC4855246.
      Citations: 1     Fields:    
    188. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ, METEOR Investigators, G?czi L. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 05; 373(19):1814-23. PMID: 26406150; PMCID: PMC5024539.
      Citations: 370     Fields:    Translation:Humans
    189. Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, Ding Z, Tannir N, Wood CG, Matin SF, Karam JA, Tamboli P, Sircar K, Rao P, Rankin EB, Laird DA, Hoang AG, Walker CL, Giaccia AJ, Jonasch E. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016 05; 35(21):2687-97. PMID: 26364599; PMCID: PMC4791213.
      Citations: 149     Fields:    Translation:HumansAnimalsCells
    190. Bilen MA, Zurita AJ, Ilias-Khan NA, Chen HC, Wang X, Kearney AY, Hodges S, Jonasch E, Huang S, Khakoo AY, Tannir NM. Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial. Oncologist. 2015 Oct; 20(10):1140-8. PMID: 26306901; PMCID: PMC4591942.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    191. Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol. 2015 Oct; 26(10):2125-32. PMID: 26199392; PMCID: PMC5006186.
      Citations: 6     Fields:    Translation:Humans
    192. Sircar K, Yoo SY, Majewski T, Wani K, Patel LR, Voicu H, Torres-Garcia W, Verhaak RG, Tannir N, Karam JA, Jonasch E, Wood CG, Tamboli P, Baggerly KA, Aldape KD, Czerniak B. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res. 2015 Oct; 1(4):212-24. PMID: 27499906; PMCID: PMC4939892.
      Citations: 5     Fields:    
    193. Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5. PMID: 26032863; PMCID: PMC4666814.
      Citations: 26     Fields:    Translation:Humans
    194. Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, Mehrotra M, Wani K, Tannir N, Karam JA, Jonasch E, Wood CG, Creighton CJ, Medeiros LJ, Broaddus RR, Tamboli P, Baggerly KA, Aldape KD, Czerniak B, Luthra R, Sircar K. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep; 28(9):1225-35. PMID: 26111976; PMCID: PMC4556533.
      Citations: 12     Fields:    Translation:HumansCells
    195. Ho TH, Park IY, Zhao H, Tong P, Champion MD, Yan H, Monzon FA, Hoang A, Tamboli P, Parker AS, Joseph RW, Qiao W, Dykema K, Tannir NM, Castle EP, Nunez-Nateras R, Teh BT, Wang J, Walker CL, Hung MC, Jonasch E. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene. 2016 Mar 24; 35(12):1565-74. PMID: 26073078; PMCID: PMC4679725.
      Citations: 37     Fields:    Translation:HumansCells
    196. Pagliaro LC, Tannir NM, Tu SM, Logothetis CJ. Management of Clinical Stage I Testicular Cancer: How Should We Define Success? J Clin Oncol. 2015 Jul 10; 33(20):2321-2. PMID: 26033805.
      Citations: 1     Fields:    Translation:Humans
    197. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29. PMID: 26014097; PMCID: PMC4561186.
      Citations: 77     Fields:    Translation:HumansAnimalsCells
    198. Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23. PMID: 26004164; PMCID: PMC4584175.
      Citations: 14     Fields:    Translation:Humans
    199. Tang C, Hess K, Bishop AJ, Pan HY, Christensen EN, Yang JN, Tannir N, Amini B, Tatsui C, Rhines L, Brown P, Ghia A. Creation of a Prognostic Index for Spine Metastasis to Stratify Survival in Patients Treated With Spinal Stereotactic Radiosurgery: Secondary Analysis of Mature Prospective Trials. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):118-25. PMID: 26130231.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    200. Yennurajalingam S, Reddy A, Tannir NM, Chisholm GB, Lee RT, Lopez G, Escalante CP, Manzullo EF, Frisbee Hume S, Williams JL, Cohen L, Bruera E. High-Dose Asian Ginseng (Panax Ginseng) for Cancer-Related Fatigue: A Preliminary Report. Integr Cancer Ther. 2015 Sep; 14(5):419-27. PMID: 25873296.
      Citations: 8     Fields:    Translation:HumansAnimalsCTClinical Trials
    201. Bishop AJ, Tao R, Rebueno NC, Christensen EN, Allen PK, Wang XA, Amini B, Tannir NM, Tatsui CE, Rhines LD, Li J, Chang EL, Brown PD, Ghia AJ. Outcomes for Spine Stereotactic Body Radiation Therapy and an Analysis of Predictors of Local Recurrence. Int J Radiat Oncol Biol Phys. 2015 Aug 01; 92(5):1016-1026. PMID: 26025777.
      Citations: 30     Fields:    Translation:Humans
    202. Thomas AZ, Adibi M, Borregales LD, Hoang LN, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol. 2015 Aug; 194(2):316-22. PMID: 25758610; PMCID: PMC4666307.
      Citations: 13     Fields:    Translation:Humans
    203. Shah AY, Karam JA, Lim ZD, Ng CS, Tannir NM. Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy? Urol Case Rep. 2015 Mar 01; 3(2):18-20. PMID: 26120560; PMCID: PMC4477704.
      Citations: 2     
    204. Shu X, Purdue MP, Ye Y, Wood CG, Chen M, Wang Z, Albanes D, Pu X, Huang M, Stevens VL, Diver WR, Gapstur SM, Virtamo J, Chow WH, Tannir NM, Dinney CP, Rothman N, Chanock SJ, Wu X. Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell carcinoma. Oncotarget. 2015 Feb 28; 6(6):4097-109. PMID: 25784652; PMCID: PMC4414175.
      Citations:    Fields:    Translation:Humans
    205. Silva JG, Corrales-Medina FF, Maher OM, Tannir N, Huh WW, Rytting ME, Subbiah V. Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations. Oncoscience. 2015; 2(2):187-92. PMID: 25859559; PMCID: PMC4381709.
      Citations: 9     
    206. Thekdi SM, Milbury K, Spelman A, Wei Q, Wood C, Matin SF, Tannir N, Jonasch E, Pisters L, Cohen L. Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening. Psychooncology. 2015 Nov; 24(11):1477-84. PMID: 25690556; PMCID: PMC4539280.
      Citations: 9     Fields:    Translation:HumansPHPublic Health
    207. Merrill MM, Wood CG, Tannir NM, Slack RS, Babaian KN, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9. PMID: 25700975; PMCID: PMC4664068.
      Citations: 20     Fields:    Translation:Humans
    208. Karam JA, Babaian KN, Tannir NM, Matin SF, Wood CG. Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma. Minerva Urol Nefrol. 2015 Jun; 67(2):149-56. PMID: 25645343.
      Citations:    Fields:    Translation:Humans
    209. Melkonian SC, Wang X, Gu J, Matin SF, Tannir NM, Wood CG, Wu X. Mitochondrial DNA copy number in peripheral blood leukocytes and the risk of clear cell renal cell carcinoma. Carcinogenesis. 2015 Feb; 36(2):249-55. PMID: 25524925; PMCID: PMC4322190.
      Citations: 12     Fields:    Translation:HumansCells
    210. Land JD, Chen AH, Atkinson BJ, Cauley DH, Tannir NM. Proteinuria with first-line therapy of metastatic renal cell cancer. J Oncol Pharm Pract. 2016 Apr; 22(2):235-41. PMID: 25505255.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    211. Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 2014 Nov 15; 5(21):10280-92. PMID: 25373733; PMCID: PMC4279372.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    212. Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun; 13(3):218-24. PMID: 25465491; PMCID: PMC4991027.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    213. Pan HY, Allen PK, Wang XS, Chang EL, Rhines LD, Tatsui CE, Amini B, Wang XA, Tannir NM, Brown PD, Ghia AJ. Incidence and predictive factors of pain flare after spine stereotactic body radiation therapy: secondary analysis of phase 1/2 trials. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):870-6. PMID: 25227497.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    214. Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, de Vos S, Hamlin PA, Kim SK, Whiting NC, Gartner EM, Zhao B, Thompson JA. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs. 2014 Dec; 32(6):1246-57. PMID: 25142258.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    215. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. 2015 Jan 01; 121(1):69-76. PMID: 25155428; PMCID: PMC4270821.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    216. Zhang J, Yuan Y, Chen Y, Thompson EJ, Tannir NM, Weinstein JN, Valero V, Su X, Malouf GG, Comp?rat E, Roupr?t M, Cussenot O, Khayat D, Spano JP. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol. 2015 Jan; 9(1):32-43. PMID: 25126716; PMCID: PMC4516270.
      Citations: 45     Fields:    Translation:Humans
    217. Melkonian SC, Daniel CR, Hildebrandt MA, Tannir NM, Ye Y, Chow WH, Wood CG, Wu X. Joint association of genome-wide association study-identified susceptibility loci and dietary patterns in risk of renal cell carcinoma among non-Hispanic whites. Am J Epidemiol. 2014 Sep 01; 180(5):499-507. PMID: 25053674; PMCID: PMC4143080.
      Citations: 8     Fields:    Translation:Humans
    218. Liu XD, Yao J, Tripathi DN, Ding Z, Xu Y, Sun M, Zhang J, Bai S, German P, Hoang A, Zhou L, Jonasch D, Zhang X, Conti CJ, Efstathiou E, Tannir NM, Eissa NT, Mills GB, Walker CL, Jonasch E. Autophagy mediates HIF2a degradation and suppresses renal tumorigenesis. Oncogene. 2015 May 07; 34(19):2450-60. PMID: 24998849; PMCID: PMC4286517.
      Citations: 41     Fields:    Translation:HumansCells
    219. Jardim DL, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS, de Melo Gagliato D. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26. PMID: 25087088; PMCID: PMC5144738.
      Citations: 10     Fields:    Translation:Humans
    220. Prinsloo S, Wei Q, Scott SM, Tannir N, Jonasch E, Pisters L, Cohen L. Psychological states, serum markers and survival: associations and predictors of survival in patients with renal cell carcinoma. J Behav Med. 2015 Feb; 38(1):48-56. PMID: 24935017; PMCID: PMC4824635.
      Citations: 4     Fields:    Translation:Humans
    221. Teegavarapu PS, Rao P, Matrana M, Cauley DH, Wood CG, Tannir NM. Neuroendocrine tumors of the kidney: a single institution experience. Clin Genitourin Cancer. 2014 Dec; 12(6):422-7. PMID: 25088468; PMCID: PMC4253079.
      Citations: 3     Fields:    Translation:Humans
    222. Malouf GG, Su X, Yao H, Gao J, Xiong L, He Q, Escudier B, Camparo P, Doss DJ, Thompson EJ, Khayat D, Wood CG, Yu W, Teh BT, Weinstein J, Tannir NM, Comp?rat E, Couturier J, Molini? V. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes. Clin Cancer Res. 2014 Aug 01; 20(15):4129-40. PMID: 24899691; PMCID: PMC4167829.
      Citations: 45     Fields:    Translation:HumansCells
    223. Tu SM, Bilen MA, Tannir NM. The scientific method: pillar and pitfall of cancer research. Cancer Med. 2014 Aug; 3(4):1035-7. PMID: 24711219; PMCID: PMC4303171.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    224. Burch-Smith R, Tannir NM, Resetkova E, Tamboli P, Rao P. Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma: report of a case with unusual morphology and clinical follow-up. Chin J Cancer. 2014 Jul; 33(7):351-5. PMID: 24589208; PMCID: PMC4110468.
      Citations: 5     Fields:    Translation:Humans
    225. Babaian KN, Merrill MM, Matin S, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. 2014 Jul; 192(1):36-42. PMID: 24518767; PMCID: PMC4502598.
      Citations: 3     Fields:    Translation:Humans
    226. Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, Tamboli P, Tannir NM, Wood CG. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. 2014 Nov; 66(5):874-80. PMID: 24560330; PMCID: PMC4396847.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    227. Milbury K, Spelman A, Wood C, Matin SF, Tannir N, Jonasch E, Pisters L, Wei Q, Cohen L. Randomized controlled trial of expressive writing for patients with renal cell carcinoma. J Clin Oncol. 2014 Mar 01; 32(7):663-70. PMID: 24470003; PMCID: PMC3927735.
      Citations: 18     Fields:    Translation:Humans
    228. Shetty AV, Matrana MR, Atkinson BJ, Flaherty AL, Jonasch E, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience. Clin Genitourin Cancer. 2014 Oct; 12(5):348-53. PMID: 24565697; PMCID: PMC4160412.
      Citations: 16     Fields:    Translation:Humans
    229. Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int. 2014 Mar; 113(3):376-82. PMID: 24053120; PMCID: PMC3944913.
      Citations: 22     Fields:    Translation:Humans
    230. Jonasch E, Allen PK, Weinberg JS, Tannir N, Chang EL, Mahajan A, Verma J. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. Am J Clin Oncol. 2013 Dec; 36(6):620-4. PMID: 22892430; PMCID: PMC4630800.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    231. Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2014 Jun; 12(3):167-177.e2. PMID: 24365125; PMCID: PMC4754667.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    232. Vin H, Ching G, Ojeda SS, Adelmann CH, Chitsazzadeh V, Dwyer DW, Ma H, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Ciurea AM, Duvic M, Busaidy NL, Tannir NM, Tsai KY. Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. Mol Cancer Ther. 2014 Jan; 13(1):221-9. PMID: 24170769; PMCID: PMC4366425.
      Citations: 12     Fields:    Translation:HumansCells
    233. Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM, Richey SL. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol. 2013 Oct; 36(5):450-4. PMID: 22706175; PMCID: PMC3882166.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    234. Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014 Mar; 191(3):611-8. PMID: 24018239; PMCID: PMC4015627.
      Citations: 48     Fields:    Translation:Humans
    235. Laguna MP. Re: Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. J Urol. 2013 Nov; 190(5):1710. PMID: 24120769.
      Citations:    Fields:    Translation:Humans
    236. Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013 Sep 01; 31(25):3076-82. PMID: 23897970.
      Citations: 100     Fields:    Translation:Humans
    237. Malouf GG, Monzon FA, Escudier B, Su X, Yao H, Tamboli P, Lopez-Terrada D, Picken M, Garcia M, Multani AS, Pathak S, Wood CG, Tannir NM, Couturier J, Molini? V, Camparo P. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res. 2013 Sep 01; 19(17):4673-84. PMID: 23817689; PMCID: PMC3882157.
      Citations: 29     Fields:    Translation:HumansCells
    238. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn P, Pagliaro LC, Millikan RE, Charnsangave C, Jonasch E, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer. 2013 Oct; 49(15):3169-75. PMID: 23810246; PMCID: PMC3882156.
      Citations: 14     Fields:    Translation:Humans
    239. Khoury JD, Tannir NM, Williams MD, Chen Y, Yao H, Zhang J, Thompson EJ, TCGA Network, Meric-Bernstam F, Medeiros LJ, Weinstein JN, Su X. Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol. 2013 Aug; 87(16):8916-26. PMID: 23740984; PMCID: PMC3754044.
      Citations: 94     Fields:    Translation:HumansCells
    240. Lim ZD, Mahajan A, Weinberg J, Tannir NM. Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy. Am J Clin Oncol. 2013 Jun; 36(3):258-60. PMID: 22441343.
      Citations: 12     Fields:    Translation:Humans
    241. Anzalone CL, Cohen PR, Migden MR, Tannir NM. Mohs surgery in metastatic cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled surgical excision. Int J Dermatol. 2013 Jul; 52(7):856-61. PMID: 23675612.
      Citations: 2     Fields:    Translation:Humans
    242. Conter HJ, Lim ZD, Ng CS, Millikan RE, Tannir NM. Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: a case report of a 55-year-old man with a 10-year complete remission. Clin Genitourin Cancer. 2013 Sep; 11(3):370-3. PMID: 23665133.
      Citations:    Fields:    Translation:Humans
    243. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3621-30. PMID: 23649003; PMCID: PMC3699964.
      Citations: 136     Fields:    Translation:Humans
    244. Karam JA, Ahrar K, Vikram R, Romero CA, Jonasch E, Tannir NM, Rao P, Wood CG, Matin SF. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int. 2013 May; 111(6):997-1005. PMID: 23510233; PMCID: PMC3637414.
      Citations: 5     Fields:    Translation:Humans
    245. Parker PA, Alba F, Fellman B, Urbauer DL, Li Y, Karam JA, Tannir N, Jonasch E, Wood CG, Matin SF. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol. 2013 Jun; 63(6):1122-7. PMID: 23419322; PMCID: PMC3866912.
      Citations: 21     Fields:    Translation:Humans
    246. Shu X, Lin J, Wood CG, Tannir NM, Wu X. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk. J Natl Cancer Inst. 2013 Mar 20; 105(6):424-32. PMID: 23378641; PMCID: PMC3601952.
      Citations: 12     Fields:    Translation:HumansCells
    247. Margulis V, Shariat SF, Rapoport Y, Rink M, Sjoberg DD, Tannir NM, Abel EJ, Culp SH, Tamboli P, Wood CG. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol. 2013 May; 63(5):947-52. PMID: 23273681; PMCID: PMC4378834.
      Citations: 26     Fields:    Translation:Humans
    248. Chen Y, Yao H, Thompson EJ, Tannir NM, Weinstein JN, Su X. VirusSeq: software to identify viruses and their integration sites using next-generation sequencing of human cancer tissue. Bioinformatics. 2013 Jan 15; 29(2):266-7. PMID: 23162058; PMCID: PMC3546792.
      Citations: 85     Fields:    Translation:HumansCells
    249. Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, Jennings NB, Scott S, Vence L, Wei Q, Kentor D, Radvanyi L, Tannir N, Jonasch E, Tamboli P, Pisters L. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One. 2012; 7(8):e42324. PMID: 22870317; PMCID: PMC3409855.
      Citations: 60     Fields:    Translation:HumansCellsCTClinical Trials
    250. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012 Dec; 62(6):1013-9. PMID: 22771265; PMCID: PMC3882163.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    251. Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Dirix LY, Fishman M, Ramlau R, Ravaud A, Rogowski W, Kracht K, Sun YN, Bass MB, Puhlmann M, Escudier B. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer. 2012 Dec 15; 118(24):6152-61. PMID: 22692704; PMCID: PMC4666535.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    252. Richey SL, Rao P, Wood CG, Patel S, Tannir NM. Metastatic extraosseous Ewing's sarcoma (EES)/primitive neuroectodermal tumor (PNET) of the kidney: 8-year durable response after induction and maintenance chemotherapy. Clin Genitourin Cancer. 2012 Sep; 10(3):210-2. PMID: 22503609; PMCID: PMC4121061.
      Citations: 4     Fields:    Translation:Humans
    253. Abel EJ, Carrasco A, Culp SH, Matin SF, Tamboli P, Tannir NM, Wood CG. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int. 2012 Dec; 110(11):1742-6. PMID: 22503066.
      Citations: 16     Fields:    Translation:Humans
    254. Rao P, Tannir NM, Tamboli P. Expression of OCT3/4 in renal medullary carcinoma represents a potential diagnostic pitfall. Am J Surg Pathol. 2012 Apr; 36(4):583-8. PMID: 22301499.
      Citations: 12     Fields:    Translation:HumansCells
    255. Milbury K, Tannir NM, Cohen L. Treatment-related optimism protects quality of life in a phase II clinical trial for metastatic renal cell carcinoma. Ann Behav Med. 2011 Dec; 42(3):313-20. PMID: 21822749.
      Citations: 3     Fields:    Translation:Humans
    256. Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, Tannir NM, Gombos DS, Fuller GN, Matin SF. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol. 2011 Dec; 22(12):2661-2666. PMID: 22105611; PMCID: PMC4542805.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    257. Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen J, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer. 2011 Dec; 47(18):2706-14. PMID: 22078932; PMCID: PMC4167844.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    258. Manoukian GE, Tannir NM, Jonasch E, Qiao W, Haygood TM, Tu SM. Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2011 Dec; 9(2):81-8. PMID: 21958521; PMCID: PMC3641665.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    259. Matrana MR, Ng C, Rao P, Lim ZD, Tannir NM. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report. Clin Genitourin Cancer. 2011 Dec; 9(2):137-9. PMID: 21831725.
      Citations: 1     Fields:    Translation:Humans
    260. Chowdhury S, Matrana MR, Tsang C, Atkinson B, Choueiri TK, Tannir NM. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. Hematol Oncol Clin North Am. 2011 Aug; 25(4):853-69. PMID: 21763971; PMCID: PMC4167832.
      Citations: 11     Fields:    Translation:Humans
    261. Matrana MR, Atkinson B, Jonasch E, Tannir NM. Emerging targeted therapies in metastatic renal cell carcinoma. Curr Clin Pharmacol. 2011 Aug; 6(3):189-98. PMID: 21827388.
      Citations: 9     Fields:    Translation:HumansAnimals
    262. Choueiri M, Tannir N, Jonasch E. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr Clin Pharmacol. 2011 Aug; 6(3):144-50. PMID: 21827393; PMCID: PMC3895463.
      Citations: 3     Fields:    Translation:HumansAnimals
    263. Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol. 2011 Dec; 60(6):1273-9. PMID: 21784574; PMCID: PMC4378714.
      Citations: 30     Fields:    Translation:Humans
    264. Monzon FA, Alvarez K, Peterson L, Truong L, Amato RJ, Hernandez-McClain J, Tannir N, Parwani AV, Jonasch E. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol. 2011 Nov; 24(11):1470-9. PMID: 21725288; PMCID: PMC4639322.
      Citations: 46     Fields:    Translation:HumansCells
    265. Pagliaro LC, Tannir N, Sircar K, Jonasch E. Systemic therapy for sarcomatoid renal cell carcinoma. Expert Rev Anticancer Ther. 2011 Jun; 11(6):913-20. PMID: 21707288.
      Citations: 2     Fields:    Translation:Humans
    266. Chapin BF, Delacroix SE, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011 Nov; 60(5):964-71. PMID: 21621907; PMCID: PMC4378825.
      Citations: 29     Fields:    Translation:Humans
    267. Richey SL, Culp SH, Jonasch E, Matin SF, Wood CG, Tannir NM. Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Ann Oncol. 2011 May; 22(5):1243. PMID: 21521725.
      Citations:    Fields:    Translation:Humans
    268. Verma J, Jonasch E, Allen P, Tannir N, Mahajan A. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer. 2011 Nov 01; 117(21):4958-65. PMID: 21484781; PMCID: PMC4167837.
      Citations: 19     Fields:    Translation:Humans
    269. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2012 Jan; 23(1):46-52. PMID: 21464158; PMCID: PMC3276320.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    270. Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol. 2011 Oct; 68(4):889-96. PMID: 21290244.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    271. Richey SL, Ng C, Lim ZD, Jonasch E, Tannir NM. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol. 2011 Mar 10; 29(8):e203-5. PMID: 21172884; PMCID: PMC4468428.
      Citations: 9     Fields:    Translation:Humans
    272. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011 Feb; 185(2):439-44. PMID: 21167518; PMCID: PMC4668716.
      Citations: 41     Fields:    Translation:Humans
    273. Jonasch E, Pagliaro LC, Tannir NM. Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Rev Anticancer Ther. 2010 Dec; 10(12):1883-9. PMID: 21110755; PMCID: PMC3895462.
      Citations: 1     Fields:    Translation:Humans
    274. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. 2011 May; 22(5):1048-1053. PMID: 21115604; PMCID: PMC4092250.
      Citations: 22     Fields:    Translation:Humans
    275. Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, Heng DY, Tannir NM. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010 Nov 15; 116(22):5219-25. PMID: 20665500; PMCID: PMC4667556.
      Citations: 46     Fields:    Translation:HumansCells
    276. Dhillon J, Tannir NM, Matin SF, Tamboli P, Czerniak BA, Guo CC. Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol. 2011 Jan; 42(1):146-50. PMID: 20971497; PMCID: PMC4163005.
      Citations: 20     Fields:    Translation:Humans
    277. Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, Wood CG. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2011 Jan; 59(1):10-5. PMID: 20952123; PMCID: PMC4378833.
      Citations: 35     Fields:    Translation:Humans
    278. Rodney AJ, Tannir NM, Siefker-Radtke AO, Liu P, Walsh GL, Millikan RE, Swisher SG, Tu SM, Pagliaro LC. Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience. Urol Oncol. 2012 Nov-Dec; 30(6):879-85. PMID: 20933444; PMCID: PMC3956468.
      Citations: 13     Fields:    Translation:Humans
    279. Jonasch E, Lal LS, Atkinson BJ, Byfield SD, Miller LA, Pagliaro LC, Feng C, Tannir NM. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int. 2011 Mar; 107(5):741-747. PMID: 21355978; PMCID: PMC4648626.
      Citations: 6     Fields:    Translation:Humans
    280. Karam JA, Ahrar K, Wood CG, Jonasch E, Vikram R, Romero C, Tannir N, Matin SF. Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol. 2010 Nov; 184(5):1882-7. PMID: 20846689; PMCID: PMC4777338.
      Citations: 2     Fields:    Translation:Humans
    281. Abel EJ, Culp SH, Matin SF, Tamboli P, Wallace MJ, Jonasch E, Tannir NM, Wood CG. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol. 2010 Nov; 184(5):1877-81. PMID: 20850148; PMCID: PMC4809737.
      Citations: 21     Fields:    Translation:Humans
    282. Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF, Wood CG. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010 Jul 15; 116(14):3378-88. PMID: 20564061.
      Citations: 66     Fields:    Translation:Humans
    283. Jonasch E, Tannir NM. Targeted therapy for locally advanced renal cell carcinoma. Target Oncol. 2010 Jun; 5(2):113-8. PMID: 20625844.
      Citations: 1     Fields:    Translation:Humans
    284. Tsavachidou-Fenner D, Tannir N, Tamboli P, Liu W, Petillo D, Teh B, Mills GB, Jonasch E. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol. 2010 Aug; 21(8):1599-1606. PMID: 20089566; PMCID: PMC4092253.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    285. Mathew P, Tannir N, Tu SM, Carter CM, Bekele NB, Pagliaro L. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol. 2010 Mar; 65(4):811-5. PMID: 20052472; PMCID: PMC4436674.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    286. Ng CS, Wang X, Faria SC, Lin E, Charnsangavej C, Tannir NM. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. AJR Am J Roentgenol. 2010 Jan; 194(1):166-71. PMID: 20028919.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    287. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2010 Jan 01; 116(1):57-65. PMID: 19862815; PMCID: PMC4636203.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    288. Dutcher JP, Tannir N, Bellmunt J, Escudier B. Experience with sorafenib and the elderly patient. Med Oncol. 2010 Dec; 27(4):1359-70. PMID: 20043216.
      Citations: 7     Fields:    Translation:Humans
    289. Chen M, Ye Y, Yang H, Tamboli P, Matin S, Tannir NM, Wood CG, Gu J, Wu X. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer. 2009 Nov 15; 125(10):2342-8. PMID: 19521957; PMCID: PMC2768265.
      Citations: 38     Fields:    Translation:HumansCells
    290. Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7061-8. PMID: 19903778; PMCID: PMC2784003.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    291. Rodney AJ, Gombos DS, Fuller GN, Pagliaro LC, Tannir NM. Choroidal and conjunctival metastases from renal cell carcinoma. Am J Clin Oncol. 2009 Aug; 32(4):448-9. PMID: 19657240.
      Citations: 5     Fields:    Translation:Humans
    292. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 01; 27(25):4076-81. PMID: 19636008; PMCID: PMC4371138.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    293. Montero AJ, Diaz-Montero CM, Millikan RE, Liu J, Do KA, Hodges S, Jonasch E, McIntyre BW, Hwu P, Tannir N. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival. Ann Oncol. 2009 Oct; 20(10):1682-7. PMID: 19541791; PMCID: PMC4542573.
      Citations: 21     Fields:    Translation:Humans
    294. Plimack ER, Tannir N, Lin E, Bekele BN, Jonasch E. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer. 2009 May 01; 115(9):1859-66. PMID: 19241453; PMCID: PMC4455934.
      Citations: 15     Fields:    Translation:Humans
    295. Vikram R, Ng CS, Tamboli P, Tannir NM, Jonasch E, Matin SF, Wood CG, Sandler CM. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics. 2009 May-Jun; 29(3):741-54; discussion 755-7. PMID: 19448113.
      Citations: 37     Fields:    Translation:Humans
    296. Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, Jones P, Yang A, Issa JP. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics. 2009 Apr 01; 4(3):176-84. PMID: 19421002; PMCID: PMC2848123.
      Citations: 29     Fields:    Translation:HumansCells
    297. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int. 2009 Aug; 104(4):456-60. PMID: 19338544; PMCID: PMC4464661.
      Citations: 16     Fields:    Translation:Humans
    298. Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer. 2009 Mar 15; 115(6):1310-7. PMID: 19156903.
      Citations: 3     Fields:    Translation:Humans
    299. Clague J, Lin J, Cassidy A, Matin S, Tannir NM, Tamboli P, Wood CG, Wu X. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):801-7. PMID: 19240244; PMCID: PMC2747496.
      Citations: 38     Fields:    Translation:Humans
    300. Rodney AJ, Gombos DS, Pagliaro LC, Tannir NM. Ischemic optic neuropathy associated with low-dose interferon alfa: report of two cases. Am J Clin Oncol. 2009 Feb; 32(1):86-7. PMID: 19194130; PMCID: PMC4121058.
      Citations: 3     Fields:    Translation:Humans
    301. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009 Jan; 7(1):20-3. PMID: 19213663; PMCID: PMC4825856.
      Citations: 29     Fields:    Translation:Humans
    302. Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology. 2009 Feb; 73(2):337-41. PMID: 18950837; PMCID: PMC4723280.
      Citations: 8     Fields:    Translation:Humans
    303. Ng CS, Wood CG, Silverman PM, Tannir NM, Tamboli P, Sandler CM. Renal cell carcinoma: diagnosis, staging, and surveillance. AJR Am J Roentgenol. 2008 Oct; 191(4):1220-32. PMID: 18806169.
      Citations: 58     Fields:    Translation:HumansPHPublic Health
    304. Jonasch E, Tannir NM. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J. 2008 Sep-Oct; 14(5):315-9. PMID: 18836336.
      Citations: 2     Fields:    Translation:Humans
    305. Jain R, Mathew P, Wood CG, Tannir NM. Sunitinib-induced acute hemolysis without hypertension: a case report. Clin Genitourin Cancer. 2008 Sep; 6(2):122-3. PMID: 18824436.
      Citations: 2     Fields:    Translation:Humans
    306. Bilen MA, Waguespack SG, Tannir NM, Pravinkumar SE, Tamboli P, Tu SM. Multisystem crisis in a patient with presumptive renal cell carcinoma. Clin Genitourin Cancer. 2008 Sep; 6(2):128-30. PMID: 18824438.
      Citations:    Fields:    Translation:Humans
    307. Lin J, Pu X, Wang W, Matin S, Tannir NM, Wood CG, Wu X. Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma. Carcinogenesis. 2008 Nov; 29(11):2112-9. PMID: 18711149; PMCID: PMC2722861.
      Citations: 11     Fields:    Translation:HumansCells
    308. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008 Sep; 180(3):867-72; discussion 872. PMID: 18635226; PMCID: PMC4167838.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    309. Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol. 2008 Jun; 144(6):779-82. PMID: 18559769.
      Citations: 10     Fields:    Translation:Humans
    310. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, Trent J, Champion JC, Durand JB, Lenihan DJ. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008 Jun; 112(11):2500-8. PMID: 18386829.
      Citations: 72     Fields:    Translation:Humans
    311. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008 Jul; 180(1):94-8. PMID: 18485389.
      Citations: 41     Fields:    Translation:Humans
    312. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer. 2008 Apr 22; 98(8):1336-41. PMID: 18362942; PMCID: PMC2361701.
      Citations: 20     Fields:    Translation:HumansPHPublic Health
    313. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM. Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol. 2008 Nov-Dec; 26(6):595-9. PMID: 18367105; PMCID: PMC4121060.
      Citations: 10     Fields:    Translation:Humans
    314. Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer. 2007 Dec 15; 110(12):2700-8. PMID: 17948916.
      Citations: 4     Fields:    Translation:Humans
    315. Spiess PE, Tannir NM, Brown GA, Liu P, Tu SM, Evans JG, Pisters LL. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology. 2007 Dec; 70(6):1173-8. PMID: 18158041.
      Citations:    Fields:    Translation:Humans
    316. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med. 2007 Nov 20; 26(26):4687-702. PMID: 17427204.
      Citations: 29     Fields:    Translation:Humans
    317. Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, Humerickhouse RA, Qian J, Gordon GB, Figlin R. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6689-95. PMID: 18006769.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    318. Spiess PE, Pettaway CA, Vakar-Lopez F, Kassouf W, Wang X, Busby JE, Do KA, Davuluri R, Tannir NM. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer. 2007 Oct 15; 110(8):1729-37. PMID: 17786954.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    319. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007 Oct 01; 13(19):5816-24. PMID: 17908974.
      Citations: 46     Fields:    Translation:Humans
    320. Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int. 2007 Oct; 100(4):765-9. PMID: 17822457.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    321. Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin S, Swanson DA, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol. 2007 Nov; 178(5):1896-900. PMID: 17868729.
      Citations: 23     Fields:    Translation:Humans
    322. Shao L, Wood CG, Zhang D, Tannir NM, Matin S, Dinney CP, Wu X. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol. 2007 Oct; 178(4 Pt 1):1492-6. PMID: 17707063.
      Citations: 44     Fields:    Translation:HumansCells
    323. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007 Aug; 89(8):1794-801. PMID: 17671020.
      Citations: 62     Fields:    Translation:Humans
    324. Nakayama K, Tannir NM, Liu P, Wathen JK, Cheng YC, Champlin RE, Ueno NT. Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):975-85. PMID: 17640602.
      Citations: 2     Fields:    Translation:Humans
    325. Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM, Pisters LL. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol. 2007 Apr; 177(4):1330-4; discussion 1334. PMID: 17382725.
      Citations: 26     Fields:    Translation:Humans
    326. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2007 Jan; 177(1):131-8. PMID: 17162023.
      Citations:    Fields:    Translation:HumansPHPublic Health
    327. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer. 2006 Nov 01; 107(9):2254-61. PMID: 17029276.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    328. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer. 2006 Oct 01; 107(7):1483-90. PMID: 16944541.
      Citations: 7     Fields:    Translation:Humans
    329. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer. 2006 Oct 01; 107(7):1503-10. PMID: 16944534.
      Citations: 7     Fields:    Translation:Humans
    330. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer. 2006 Aug 01; 107(3):497-505. PMID: 16795067.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    331. Rodney A, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer. 2006 May 15; 106(10):2143-7. PMID: 16598751.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    332. Ahrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME. Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. J Vasc Interv Radiol. 2005 May; 16(5):679-88. PMID: 15872323.
      Citations: 20     Fields:    Translation:Humans
    333. Thall PF, Wooten LH, Tannir NM. Monitoring event times in early phase clinical trials: some practical issues. Clin Trials. 2005; 2(6):467-78. PMID: 16422307.
      Citations: 18     Fields:    Translation:Humans
    334. Ueno NT, Cheng YC, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE, Rond?n G. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003 Nov 15; 102(10):3829-36. PMID: 12881308.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    335. Tannir N, Ahrar K, Wood CG, S?nchez-Ortiz RF. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J Urol. 2003 Jul; 170(1):178-9. PMID: 12796677.
      Citations: 38     Fields:    Translation:Humans
    336. Tannir NM, Kantarjian H. Idiopathic thrombocytopenic purpura following successful treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 2001 Mar; 41(1-2):217-20. PMID: 11342378.
      Citations:    Fields:    Translation:Humans
    337. Tannir NM, Talpaz M, Ghazal H, Proothi S, Kantarjian HM. Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia. Leuk Lymphoma. 2000 Nov; 39(5-6):647-50. PMID: 11342349.
      Citations: 5     Fields:    Translation:Humans
    338. Mehta KU, Gascon P, Tannir N, Lombardo J, Robboy SJ. Impaired bone marrow in AIDS. N J Med. 1989 Aug; 86(8):623-7. PMID: 2685666.
      Citations:    Fields:    Translation:HumansCells
    339. Hagemeister FB, Tannir N, McLaughlin P, Salvador P, Riggs S, Velasquez WS, Cabanillas F. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol. 1987 Apr; 5(4):556-61. PMID: 3559649.
      Citations: 14     Fields:    Translation:Humans
    340. Kouttab N, Tannir N, Pathak S, Berger A, Sahasrabuddhe CG, Maizel AL. Establishment of stable human T-T hybridomas. J Immunol Methods. 1985 Feb 28; 77(1):165-72. PMID: 3871822.
      Citations: 1     Fields:    Translation:HumansCells
    341. Tannir N, Riggs S, Velasquez W, Samaan N, Manning J. Hypercalcemia, unusual bone lesions, and human T-cell leukemia-lymphoma virus in adult T-cell lymphoma. Cancer. 1985 Feb 01; 55(3):615-9. PMID: 2981152.
      Citations: 4     Fields:    Translation:HumansCells
    342. Kouttab NM, Mehta S, Morgan J, Tannir N, Sahasrabuddhe C, Maizel AL. Lymphokines and monokines as regulators of human lymphoproliferation. Clin Chem. 1984 Sep; 30(9):1539-45. PMID: 6432365.
      Citations: 4     Fields:    Translation:HumansCells
    343. Tannir N, Yap HY, Hortobagyi GH, Hug V, Buzdar AU, Blumenschein GR. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. Cancer Treat Rep. 1984 Jul-Aug; 68(7-8):1039-41. PMID: 6547638.
      Citations: 2     Fields:    Translation:Humans
    344. Tannir N, Spitzer G, Dicke K, Schell F, DiStefano A, Blumenschein G. Phase I-II study of high-dose mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer. Cancer Treat Rep. 1984 May; 68(5):805-6. PMID: 6426793.
      Citations: 1     Fields:    Translation:Humans
    345. Tannir N, Cabanillas F. Bone marrow transplantation and salvage chemotherapy. J Clin Oncol. 1984 Jan; 2(1):65-6. PMID: 6366147.
      Citations:    Fields:    Translation:Humans
    346. Tannir NM, Cortas N, Allam C. A functioning catecholamine-secreting vagal body tumor. A case report and review of the literature. Cancer. 1983 Sep 01; 52(5):932-5. PMID: 6347360.
      Citations: 3     Fields:    Translation:HumansCells
    347. Tannir NM, Spitzer G, Zander AR, Jagannath S, Kanojia M, Vellekoop L, McLaughlin P, Hagemeister FJ, Dicke KA. High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma. Eur J Cancer Clin Oncol. 1983 Aug; 19(8):1091-6. PMID: 6352279.
      Citations: 2     Fields:    Translation:Humans
    348. Tannir N, Hagemeister F, Velasquez W, Cabanillas F. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol. 1983 Jul; 1(7):432-9. PMID: 6199478.
      Citations: 2     Fields:    Translation:Humans
    349. Tannir N, Spitzer G, Schell F, Legha S, Zander A, Blumenschein G. Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer. Cancer Treat Rep. 1983 Jun; 67(6):599-600. PMID: 6344995.
      Citations:    Fields:    Translation:Humans
    350. Uwaydah M, Tannir N, Kantarjian H, Osseiran M, Bal'a F. Moxalactam therapy of bacterial meningitis in adults. Antimicrob Agents Chemother. 1983 Feb; 23(2):289-92. PMID: 6220673; PMCID: PMC186039.
      Citations: 6     Fields:    Translation:HumansCells
    351. Faris A, Tannir N, Khouri K, Salt? I. Rapid correction by 1-alpha-hydroxycholecalciferol of hemichorea in surgical hypoparathyroidism. J Neurol Neurosurg Psychiatry. 1982 Jan; 45(1):89-90. PMID: 7062078; PMCID: PMC491274.
      Citations: 2     Fields:    Translation:Humans
    352. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation. Journal of Urology.
    353. Osseous pseudoprogression in vertebral bodies treated with stereotactic radiosurgery. American Journal of Neuroradiology. 37:387-392.
    354. Authors' response. Radiographics. 29:757.
    355. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Molecular Oncology. 9:32-43.
    356. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. Journal for ImmunoTherapy of Cancer. 4.
    357. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations. 33:166.e21-166.e29.
    358. Combinatorial and sequential targeted therapy in metastatic renal cell carcinoma. 225-240.
    359. Genomic DNA hypomethylation and risk of renal cell carcinoma. Clinical Cancer Research. 22:2074-2082.
    360. Outcomes of Adults With Ewing Sarcoma Family of Tumors (ESFT) of the Kidney. American Journal of Clinical Oncology: Cancer Clinical Trials.
    361. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. Journal of Urology.
    362. Can the spinal instability neoplastic score prior to spinal radiosurgery predict compression fractures following stereotactic spinal radiosurgery for metastatic spinal tumor?. Journal of Neuro-Oncology. 126:509-517.
    363. Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell carcinoma. Oncotarget. 6:4097-4109.
    364. Tumor mutational load and immune parameters across metastatic renal cell carcinoma risk groups. Cancer immunology research. 4:820-822.
    365. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urologic Oncology: Seminars and Original Investigations.
    366. Targets by organ site.
    367. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. Journal of Clinical Oncology. 34:3562-3569.
    368. Stereotactic Body Radiation Therapy for Spinal Metastases in the Postoperative Setting. International Journal of Radiation Oncology Biology Physics.
    369. Linking Gene Mutations to Clinical Outcomes and Response to Therapy in Clear-cell Renal Cell Carcinoma. European Urology. 71:415-416.
    370. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma. Modern Pathology. 28:1225-1235.
    371. Management and outcomes of patients with renal medullary carcinoma. BJU International.
    372. Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mrcc) treated with sunitinib. Urology Case Reports. 3:18-20.
    373. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. European Urology. 66:874-880.
    374. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. Clinical Genitourinary Cancer.
    375. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU International.
    376. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN). European Urology.
    377. Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations. Oncoscience. 2:187-192.
    378. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Annals of Oncology. 26:2125-2132.
    379. Proteinuria with first-line therapy of metastatic renal cell cancer. Journal of Oncology Pharmacy Practice. 22:235-241.
    380. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clinical Genitourinary Cancer. 13:218-224.
    381. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations. 33:427.e17-427.e23.
    382. Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. BMC Cancer. 16.
    383. Reply from authors re. European Urology. 62:1022.
    384. DNA methylation signature reveals cell ontogeny of renal cell carcinomas. Clinical Cancer Research. 22:6236-6246.
    385. Posttraumatic stress and depressive symptoms in renal cell carcinoma. Psycho-Oncology.
    386. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors [Ann Oncol, 26, (2015), 2125-2132] doi. Annals of Oncology. 26:2507-2508.
    387. Reply. Urologic Oncology: Seminars and Original Investigations. 27:218-219.
    388. Management of non-clear cell renal cell carcinoma. 373-385.
    389. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene.
    390. Outcomes for Spine Stereotactic Body Radiation Therapy and an Analysis of Predictors of Local Recurrence. International Journal of Radiation Oncology Biology Physics.
    391. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic Renal cell carcinoma. Cancer immunology research. 3:1017-1029.
    392. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. Oncotarget. 6:39865-39876.
    393. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene.
    394. Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma. Journal of Neurosurgery: Spine. 24:829-836.
    395. MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. British Journal of Cancer. 116:77-84.
    396. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR). The Lancet Oncology. 17:917-927.
    397. Hypertension and circulating cytokines and angiogenic factors in patients with advanced non-clear cell renal cell carcinoma treated with sunitinib. Oncologist. 20:1140-1148.
    398. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. European Urology.
    399. Examination of moderators of expressive writing in patients with renal cell carcinoma. Psycho-Oncology.
    TANNIR's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (770)
    Explore
    _
    Co-Authors (242)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _